Lapatinib disrupts proliferation of cancer stem cells
November 2013
University Hospital of South Manchester NHS Foundation trust, Manchester, United Kingdom(1)
University of Manchester, Manchester, United Kingdom(2)
University of Manchester, Manchester, United Kingdom(2)
A combination of invasive and non-invasive interventions in patients of ductal carcinoma in situ has reduced recurrence rates, but not mortality. This is thought to be because of the survival of cancer stem cells resistant to radiotherapy. HER2 is overexpressed in 20% of ductal carcinoma in situ and highly active in cancer stem cells. Thus, Lapitinib's effects on ductal carcinoma in situ cancer stem cells were investigated. Human ductal carcinoma in situ cell lines and samples from patients were used to perform mammosphere assays and to differentiate in 3D culture to investigate the effects of Lapatinib in cancer stem cells and non-cancer stem cells. The results showed a decrease in mammosphere formation and cancer stem cell proliferation without affecting cancer stem cell self-renewal, regardless of HER2 expression. However, Lapatinib only affected the proliferation of HER2+ cells in the differentiation model. Overall, the researchers elucidate the effects of Lapatinib on ductal carcinoma in situ cancer stem cells and suggest its potential use in high-risk patients to reduce the tumour progression to metastasis.
Lapatinib inhibits stem/progenitor proliferation in preclinical in vitro models of ductal carcinoma in situ (DCIS)
Nigel Bundred(1), Gillian Farnie(2)
Added on: 10-11-2021
[1] https://www.tandfonline.com/doi/abs/10.4161/cc.27201[2] https://data.jrc.ec.europa.eu/dataset/ffebe454-ed9a-47cf-8a33-8cf70c1b7d38
